EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improved Resolution of Influenza Vaccination Responses With High‐Throughput Live Virus Microneutralisation

Lorin Adams iD, Phoebe Stevenson-Leggett iD, Jia Le Lee iD, James Bazire iD, Giulia Dowgier iD, Agnieszka Hobbs, Chloë Roustan, Annabel Borg, Christine Carr, Silvia Innocentin iD, Louise M C Webb iD, Callie Smith iD und 8 weitere

Influenza and Other Respiratory Viruses · 2025-08 · 19 (8)

DOI: 10.1111/irv.70140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, online erschienen am 14.08.2025. Verfasst von Lorin Adams und 19 weiteren Autor:innen. Beteiligte Einrichtung: Worldwide Influenza Centre, The Francis Crick Institute, London, UK. Hauptthemen laut MEDLINE: Influenza Vaccines, Antibodies, Viral, Neutralization Tests, Influenza, Human. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Biotechnology and Biological Sciences Research Council, UK Research and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Influenza remains a significant threat to human and animal health. Assessing serological protection against influenza has relied upon haemagglutinin inhibition (HAI) assays, which are used to gauge existing immune landscapes, seasonal vaccine decisions and in systems vaccinology studies. HAI assays were first described in the 1940s. Here, we adapt our high‐throughput live virus microneutralisation (LV‐N) assay for SARS‐CoV‐2, benchmark against HAI assays, and report serological vaccine responsiveness in a cohort of older (> 65 yo) community dwelling adults.

Methods

Influenza‐specific antibody responses were assessed in 73 individuals, before and after receipt of the adjuvanted 2021–22 Northern Hemisphere quadrivalent vaccine. We performed both HAI and LV‐N assays against all four viruses represented in the vaccine [A/Cambodia/e0826360/2020 (H3N2), IVR‐215 (A/Victoria/2570/2019‐like) (H1N1)pdm09, B/Phuket/3073/2013 (B/Yamagata lineage), B/Washington/02/2019 (B/Victoria lineage)], using sera drawn before vaccination [range: d‐82 to d‐5], and days 7 [d6–10] and 181 [d156–200] after vaccination. We compared serological responses within each assay and between assays.

Results

Both the traditional HAI assay and our high‐throughput live virus microneutralisation identified vaccine‐induced boosts in antibody titres. We found population‐level concordance between the two assays (Spearman's correlation coefficient range 0.49–0.88; all p ≤ 1.4 × 10 −5 ). The improved granularity of microneutralisation was better able to estimate fold changes of responses and quantify the inhibitory effect of pre‐existing antibody.

Conclusions

Our high‐throughput method offers an alternative approach to assess influenza‐specific serological responses with improved resolution, with the potential to improve the annual assessment of existing antibody landscapes, to improve new vaccine strain evaluation, and to offer a step‐change in systems vaccinology, and a facet of laboratory‐based pandemic preparedness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesAntibodies, ViralNeutralization TestsInfluenza, HumanHumansAgedFemaleMaleAntibodies, NeutralizingHigh-Throughput Screening AssaysVaccinationHemagglutination Inhibition TestsSARS-CoV-2Aged, 80 and overInfluenza A Virus, H1N1 Subtype

Stichwörter der Autor:innen

haemagglutinin inhibition assaysinfluenzalive virus microneutralisationvaccine

Substanzen

Influenza VaccinesAntibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • Worldwide Influenza Centre, The Francis Crick Institute, London, UK.
  • COVID Surveillance Unit, The Francis Crick Institute, London, UK.
  • Immunology Program, Babraham Institute, Cambridge, UK.
  • The Francis Crick Institute, London, UK.
  • UCL Centre for Kidney & Bladder Health, Royal Free Hospital, London, UK.

ORCID-Profile: Lorin Adams, Phoebe Stevenson-Leggett, Jia Le Lee, James Bazire, Giulia Dowgier, Silvia Innocentin, Louise M C Webb, Callie Smith, Nicola Lewis, Nicola O'Reilly, Svend Kjaer, Michelle A Linterman, Mary Y Wu, Edward J Carr

Förderung

  • Medical Research Council
  • Biotechnology and Biological Sciences Research Council
  • UK Research and Innovation
  • NIAID NIH HHS
  • Cancer Research UK
  • Wellcome Trust
  • NIHR Cambridge Biomedical Research Centre
  • Dunhill Medical Trust

Zitieren

APA

Adams, L., Stevenson-Leggett, P., Lee, J. L., Bazire, J., Dowgier, G., Hobbs, A., Roustan, C., Borg, A., Carr, C., Innocentin, S., Webb, L. M. C., Smith, C., Bawumia, P., Lewis, N., O'Reilly, N., Kjaer, S., Linterman, M. A., Harvey, R., Wu, M. Y., & Carr, E. J. (2025). Improved Resolution of Influenza Vaccination Responses With High‐Throughput Live Virus Microneutralisation. Influenza and Other Respiratory Viruses, 19(8). https://doi.org/10.1111/irv.70140

Vancouver

Adams L, Stevenson-Leggett P, Lee JL, Bazire J, Dowgier G, Hobbs A, et al. Improved Resolution of Influenza Vaccination Responses With High‐Throughput Live Virus Microneutralisation. Influenza and Other Respiratory Viruses. 2025;19(8). doi:10.1111/irv.70140

BibTeX
@article{Adams2025,
  author = {Adams, Lorin and Stevenson-Leggett, Phoebe and Lee, Jia Le and Bazire, James and Dowgier, Giulia and Hobbs, Agnieszka and Roustan, Chloë and Borg, Annabel and Carr, Christine and Innocentin, Silvia and Webb, Louise M C and Smith, Callie and Bawumia, Philip and Lewis, Nicola and O'Reilly, Nicola and Kjaer, Svend and Linterman, Michelle A and Harvey, Ruth and Wu, Mary Y and Carr, Edward J},
  title = {Improved Resolution of Influenza Vaccination Responses With High‐Throughput Live Virus Microneutralisation},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2025},
  volume = {19},
  number = {8},
  doi = {10.1111/irv.70140}
}
Kostenlos starten →